OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

by · The Markets Daily

StockNews.com upgraded shares of OPKO Health (NASDAQ:OPK – Free Report) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.

A number of other research analysts have also weighed in on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th.

Get Our Latest Analysis on OPKO Health

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.48 on Tuesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.63. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $1.76. The company has a fifty day moving average of $1.54 and a two-hundred day moving average of $1.50.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 280,183 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were purchased at an average cost of $1.50 per share, with a total value of $420,274.50. Following the purchase, the chief executive officer now directly owns 211,512,405 shares in the company, valued at approximately $317,268,607.50. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders purchased a total of 1,304,255 shares of company stock valued at $2,024,605 over the last 90 days. 47.26% of the stock is owned by company insiders.

Institutional Trading of OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. World Investment Advisors LLC purchased a new position in OPKO Health in the third quarter valued at $61,000. Virtu Financial LLC purchased a new position in shares of OPKO Health in the 3rd quarter valued at about $120,000. Barclays PLC raised its position in shares of OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the third quarter worth approximately $45,000. Finally, XTX Topco Ltd boosted its holdings in OPKO Health by 166.5% in the third quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 67,883 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

Featured Stories